Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$196.00
|
|
Trading Report for (ABT). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Datamonitor
|
$175.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Abbott Laboratories Issues FY 2013 EPS Guidance
Abbott Laboratories announced that it is issuing ongoing earnings-per-share guidance for fiscal 2013 of $1.98 to $2.04. The Company forecasts net specified items for fiscal 2013 of approximately $0.59 per share, primarily associated with intangible amortization expense, separation costs and cost-reduction initiatives. Including these net specified items, projected earnings per share under Generally Accepted Accounting Principles (GAAP) would be $1.39 to $1.45 for fiscal 2013.
Latest Developments for Abbott Laboratories
- Abbott Laboratories Announces New $3 Billion Share Repurchase Program; Declares Dividend
- Abbott Laboratories Announces CE Mark For Coronary Drug Eluting Stent
- Russia Rejects Abbott Laboratories Plan To Buy Petrovax-Reuters
- Abbott Laboratories Announces FDA Approval And U.S. Launch Of TECNIS Toric Intraocular Lens For Cataract Patients
Latest Key Developments in Pharmaceuticals
- USFDA Issues Warning Letter To RPG Life Sciences Ltd-Business Standard
- Alk Abello A/S Announces Positive Outcome of Pivotal Phase III Trial with Allergy Immunotherapy Tablet against House Dust Mite Allergy
- EU Fines Ranbaxy Laboratories Ltd And Others For Blocking Cheaper Drugs-Business Standard
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 Million-DJ
- Share this
- Link this
- Digg this
Follow Reuters